Ajanta Pharma Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 6/6
Ajanta Pharma verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 10.6%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 13.3%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 12.6%. Die Eigenkapitalrendite von Ajanta Pharma beträgt 23.8% und die Nettomargen betragen 19.5%.
Wichtige Informationen
10.6%
Wachstumsrate der Gewinne
11.6%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 17.5% |
| Wachstumsrate der Einnahmen | 12.6% |
| Eigenkapitalrendite | 23.8% |
| Netto-Marge | 19.5% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06Aufschlüsselung der Einnahmen und Ausgaben
Wie Ajanta Pharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 44,908 | 8,750 | 10,215 | 0 |
| 30 Jun 24 | 43,326 | 8,538 | 9,828 | 0 |
| 31 Mar 24 | 42,087 | 8,162 | 9,122 | 0 |
| 31 Dec 23 | 40,365 | 7,357 | 9,031 | 0 |
| 30 Sep 23 | 39,031 | 6,602 | 8,642 | 0 |
| 30 Jun 23 | 38,128 | 6,215 | 8,280 | 0 |
| 31 Mar 23 | 37,426 | 5,880 | 7,978 | 0 |
| 31 Dec 22 | 37,311 | 6,169 | 7,383 | 0 |
| 30 Sep 22 | 35,972 | 6,742 | 7,081 | 0 |
| 30 Jun 22 | 35,439 | 7,136 | 6,821 | 0 |
| 31 Mar 22 | 33,410 | 7,127 | 6,571 | 0 |
| 31 Dec 21 | 32,275 | 7,207 | 6,301 | 0 |
| 30 Sep 21 | 31,384 | 7,056 | 6,041 | 0 |
| 30 Jun 21 | 29,695 | 6,799 | 5,745 | 0 |
| 31 Mar 21 | 28,897 | 6,539 | 5,523 | 0 |
| 31 Dec 20 | 28,148 | 6,238 | 5,354 | 0 |
| 30 Sep 20 | 27,173 | 5,547 | 5,196 | 0 |
| 30 Jun 20 | 26,441 | 5,008 | 5,065 | 0 |
| 31 Mar 20 | 25,879 | 4,677 | 4,890 | 0 |
| 31 Dec 19 | 24,211 | 4,274 | 4,831 | 0 |
| 30 Sep 19 | 22,550 | 3,868 | 4,755 | 0 |
| 30 Jun 19 | 21,563 | 3,958 | 4,639 | 0 |
| 31 Mar 19 | 20,554 | 3,870 | 4,503 | 0 |
| 31 Dec 18 | 20,654 | 3,926 | 4,428 | 0 |
| 30 Sep 18 | 21,674 | 4,731 | 4,252 | 0 |
| 30 Jun 18 | 21,636 | 4,796 | 4,089 | 0 |
| 31 Mar 18 | 21,258 | 4,686 | 3,908 | 0 |
| 31 Dec 17 | 20,590 | 4,882 | 3,574 | 0 |
| 30 Sep 17 | 20,050 | 4,833 | 3,397 | 0 |
| 30 Jun 17 | 19,805 | 4,821 | 3,224 | 0 |
| 31 Mar 17 | 19,833 | 5,068 | 3,060 | 0 |
| 31 Dec 16 | 19,386 | 4,908 | 3,097 | 0 |
| 30 Sep 16 | 18,821 | 4,622 | 2,971 | 0 |
| 30 Jun 16 | 18,072 | 4,350 | 2,886 | 0 |
| 31 Mar 16 | 17,340 | 4,156 | 2,773 | 0 |
| 31 Dec 15 | 16,809 | 3,692 | 5,446 | 0 |
| 30 Sep 15 | 16,160 | 3,510 | 5,318 | 0 |
| 30 Jun 15 | 15,502 | 3,340 | 5,158 | 0 |
| 31 Mar 15 | 14,736 | 3,099 | 2,167 | 0 |
| 31 Mar 14 | 12,083 | 2,339 | 4,096 | 0 |
Qualität der Erträge: AJANTPHARM hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: AJANTPHARMDie aktuellen Gewinnspannen (19.5%) sind höher als im letzten Jahr (16.9%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: AJANTPHARMIn den letzten 5 Jahren sind die Gewinne von 10.6% jährlich gestiegen.
Beschleunigtes Wachstum: AJANTPHARMDas Gewinnwachstum des Unternehmens im letzten Jahr (32.5%) übertrifft seinen 5-Jahres-Durchschnitt (10.6% pro Jahr).
Erträge im Vergleich zur Industrie: AJANTPHARM Das Gewinnwachstum im vergangenen Jahr (32.5%) übertraf das der Branche Pharmaceuticals 20.5% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: AJANTPHARMDie Eigenkapitalrendite des Unternehmens (23.8%) wird als hoch angesehen.